Sawai Cites Broader Supply Issue As It Plots Construction Of A New Facility
New Solid Dosage Form Facility Planned At Its Local Daini Kyushu Site
Executive Summary
Japan’s Sawai was cautioned by one analyst earlier this year that it lacked sufficient excess production capacity to handle the sharp expansion in demand for its products. Now the company has announced plans to build a new solid dosage form facility.
You may also be interested in...
Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
Keppra And Velcade Rivals Among Sawai’s New Listings
Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.
Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako
Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.